AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
16.8 C
New York
Wednesday, October 21, 2026

Tag: clinical trial

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency...

PlaDeo: Europe Debut for the World’s First Bio-Plasma Powered Deodorant Device

CES Award-Winning Korean Innovation Now Targets EU Consumers Seeking Safe and Sustainable Hygiene SEOUL, South Korea, June 30, 2025 /PRNewswire/ -- CodeSteri Inc., a bio-tech startup...

Theranos Makes a Big Bang at the FDA

PALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Today marks a significant milestone for theranos and its diagnostic technology. The theranos system performs automated sample processing and analysis to produce clinical test results. The U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) has affirmed that the core technology is not under question.

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives “Oscar of Italian Dermatology”

Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26,...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial